lixisenatide + insulin glargine (Soliqua)

Original post, click here

Generic Name: lixisenatide + insulin glargine

Brand Name: Soliqua

Manufacturer: sanofi-aventis Canada Inc.

Indications: Diabetes mellitus, Type 2

Manufacturer Requested Reimbursement Criteria1:

​As per indication.

Submission Type: New Combination

Project Status: Pending

Call For Patient Input: March 21, 2018

Patient Input Closed: May 10, 2018

Anticipated Date: April 19, 2018

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback